Acute profound thrombocytopenia following abciximab therapy

Annals of Pharmacotherapy

Volumn 34, Issue 7-8, 2000, Pages 924-930

  Bishara, Amira I ^a   Hagmeyer, Kathleen O ^b  

^a TOLEDO HOSPITAL   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Abciximab; Hemorrhage; Immunoglobulin; Ischemia; Thrombocytopenia

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

AGED; ARTICLE; CASE REPORT; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0033929823     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19299     Document Type: Article

References (34)

1. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-31.
2. Package insert. ReoPro (abciximab). Leiden, the Netherlands: Centocor B.V., 1997.
3. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 tab (abciximab) therapy. Circulation 1997; 95:809-13.
4. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
5. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80.
6. Byzova TV, Rabbani R, D'Souza S, Plow EF. Role of integrin αvβ3 in vascular biology. Thromb Haemost 1998;80:726-34.
7. Package insert. Integrelin (eptifibatide). San Francisco: Cor Therapeutics, 1998.
8. Package insert. Aggrastat (tirofiban hydrochloride). West Point, PA: Merck & Co., 1998.
9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
10. The IMPACT II Investigators. Randomized placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
11. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
12. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
13. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338: 1498-505.
14. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
15. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
16. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
17. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. Circulation 1999;100:1016-30.
18. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999;281:1407-14.
19. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy (letter). Circulation 1997;96:3810.
20. Mak KH, Kottke-Marchant K, Brooks LM, Apheart KL, Topol EJ. Potential value of platelet GPIIb/IIIa antagonist for treating heparin-induced thrombocytopenia (HIT) (abstract). J Am Coll Cardiol 1996;27:316A.
21. Boughton BJ, Cooke RM, Smith NA, Simpson AW. Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmunity 1994;18: 141-4.
22. Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994;84: 176-83.
23. Frelinger AL III, Cohen I, Plow EF, Smith MA, Roberts J, Lam SC, et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990;265:6346-52.
24. Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kubler W, et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999;84:519-24.
25. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311-9.
26. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999;61:205-8.
27. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-5.
28. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
29. Gupta AK, Kovacs MJ, Sauder DN. Heparin-induced thrombocytopenia. Ann Pharmacother 1998;32:55-9.
30. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-3.
31. Beutler E. Platelet transfusions: the 20,000/microL trigger. Blood 1993; 81:1411-3.
32. Lee EJ. Indications for platelet transfusion therapy. In: Kurtz SR, Brubaker DB, eds. Clinical decisions in platelet therapy. Bethesda, MD: American Association of Blood Banks, 1992:31-43.
33. Murphy S. A critical view of prophylactic platelet transfusion. In: Kurtz SR, Brubaker DB, eds. Clinical decisions in platelet therapy. Bethesda, MD: American Association of Blood Banks, 1992:45-54.
34. Jenkins LA, Lau S, Crawford M, Keung YK. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy (letter). Circulation 1998;97:1214-5.